Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Company announcement – No. 50 / 2024...
Zealand Pharma Announces Financial Results for the First Nine Months of 2024 Company announcement – No. 49 / 2024 Zealand Pharma Announces Financial Results for the First Nine Months of 2024...
Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism Company announcement – No. 48 / 2024 Zealand Pharma provides U.S. regulatory update on dasiglucagon in...
Zealand Pharma announces that Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two Phase III trials in MASH for survodutide Company announcement – No. 47 / 2024 Zealand...
Total number of shares and voting rights in Zealand Pharma A/S on September 30, 2024 Company announcement – No. 46 / 2024 Total number of shares and voting rights in Zealand Pharma A/S on...
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Company announcement – No. 45 / 2024 Zealand Pharma Increases its Share Capital as a Consequence of...
Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide Company announcement – No. 44 /...
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Company announcement – No. 43 / 2024...
Total number of shares and voting rights in Zealand Pharma on August 30, 2024 Company announcement – No. 42 / 2024 Total number of shares and voting rights in Zealand Pharma on August 30, 2024...
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Company announcement – No. 41 / 2024 Zealand Pharma Increases its Share Capital as a Consequence of...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 3.45 | 3.68392952483 | 93.65 | 100.6 | 93.65 | 694 | 97.18551873 | DE |
| 4 | -9.1 | -8.56873822976 | 106.2 | 119.5 | 88.05 | 1564 | 103.24139673 | DE |
| 12 | -13.5 | -12.2061482821 | 110.6 | 124.5 | 88.05 | 1630 | 108.37567261 | DE |
| 26 | 14.45 | 17.4833635814 | 82.65 | 132.5 | 81.099999 | 2136 | 111.70369965 | DE |
| 52 | 53.02 | 120.281306715 | 44.08 | 132.5 | 44.02 | 2602 | 95.525703 | DE |
| 156 | 62.56 | 181.123335263 | 34.54 | 132.5 | 34.04 | 2115 | 94.87285342 | DE |
| 260 | 62.56 | 181.123335263 | 34.54 | 132.5 | 34.04 | 2115 | 94.87285342 | DE |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
